Quoin Pharmaceuticals (Quoin Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Jun. 13, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Forward Dividend Yield %?

As of today (2024-06-13), the Forward Annual Dividend Yield of Quoin Pharmaceuticals is 0.00%.

As of today (2024-06-13), the Trailing Annual Dividend Yield of Quoin Pharmaceuticals is 0.00%.

QNRX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.655
* Ranked among companies with meaningful Forward Dividend Yield % only.

Quoin Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Quoin Pharmaceuticals's Forward Dividend Yield %

For the Biotechnology subindustry, Quoin Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quoin Pharmaceuticals's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Forward Dividend Yield % falls into.

Quoin Pharmaceuticals Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Quoin Pharmaceuticals (NAS:QNRX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Quoin Pharmaceuticals Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349

Website

https://www.quoinpharma.com

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Executives

Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper	director	PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell	director	C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn	officer: Chief Financial Officer	AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter	director, officer: Chief Operating Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers	director, officer: Chief Executive Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101